Clinical Research

The future of healthcare, in your hands.

In close partnership with Javara, we offer clinical trials for a range of health issues and conditions. Join us in these important studies. With your help, we will find solutions to our most pressing medical challenges, and ensure that healthcare is working effectively and equitably for all.

To participate in one of these trials, call 704-586-9386 or email [email protected].

Transportation to and from clinical research visits can be arranged at no cost. To stay updated on the latest news about clinical trials, sign up for Tryon Medical Partners’ email newsletter.

Clinical trials coming soon. Contact us for more information:
  • Celiac Disease
  • Fatty Liver Disease (also called NASH or NAFLD)
Currently enrolling trials:

Asthma

You may qualify to participate if you are 18 years or older and are initiating treatment with DUPIXENT. The study will require multiple clinical study visits and qualified participants will be compensated for your time.

COPD
You may qualify to participate if you are between 40 and 85 years of age, are a current smoker or have a history of smoking and have worsening of COPD symptoms that have required hospitalization or antibiotics and steroids within the past year while on stable inhaled medication. The study will require multiple clinical study visits and qualified participants will be compensated for your time.

Colon Cancer Screening
We have availability for two colon cancer screening studies that can provide significant compensation to help offset the out-of-pocket expenses for patients’ colon cancer screening examinations (colonoscopy). Many patients can participate in both studies requiring only a stool sample and blood draw.

You may qualify to participate if you are 40 years or older. You must show zero symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy. Qualified participants will be compensated for your time.

Inflammatory Bowel Disease

CorEvitas Patient Registry
This registry is for patients on Humira, Simponi, Remicade, Stelara, Xeljanz or other major IBD medications. This is a longitudinal patient registry that is very important to track the long term efficacy and side effects of these medications. We encourage all eligible patients to consider registering.

Crohn’s Disease
You may qualify to participate if you are 18 to 80 years of age, have moderate to severe active CD, Inadequate response, loss of response, or intolerance to a conventional or biologic treatment. Qualified participants will be compensated for your time. 

Ulcerative Colitis
You may qualify for this study if you are a male or female aged 18 to 75 years old and are currently showing signs of moderate to severe active Ulcerative Colitis. Should you qualify for participation, you will be in the study for approximately 21 weeks including up to 7 clinic visits during the screening, treatment, and follow-up phases. Qualified participants will be compensated for your time. 

Gastroesophageal Reflux Disease (GERD)
This study is for patients who experience inflammation in their esophagus despite therapy.

Gastroparesis
You may qualify to participate if you are 18 and older and suffer from gastroparesis (delayed stomach emptying), whether or not you suffer from diabetes. If you volunteer and qualify for the study, your participation could last up to 20 weeks (including the Screening and Follow-up Periods) and qualified participants will be compensated for your time.

Hypertension
You may be able to participate in this study if you are 18 years of age or older, have been diagnosed with Hypertension or are taking two or more antihypertensive medications.

RSV
You may be able to participate in an RSV Vaccine research trial if you are 60 years of age or older and in good health as determined by medical history and physical examination.

 

To participate in one of these trials, please call 704-586-9386 or [email protected].

To stay updated on the latest news about clinical trials, sign up for Tryon Medical Partners’ email newsletter.